RPG Life Sciences Share Price Today (RPGLIFE)
TODAY IN ONE LINE
RPGLIFE edged up 0.4% on light volume, outperforming Nifty's -0.7% move, supported by recent strong earnings.
With a market cap of ₹4,978.16 Cr., it trades at a P/E of 43.37. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
RPG Life Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 23.6% and Profit up 33.7%
- ●High Capital EfficiencyROCE of 25.7% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.3%
- ●Healthy Operating MarginsOPM is structurally strong at 20.9%
- ●High Promoter HoldingPromoters hold 73.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 74.5% YoY
- ●Rising Receivables vs SalesReceivables grew 57.2% outpacing sales growth of 12.3%
Latest RPG Life Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
RPG Life Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for RPG Life Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
RPG Life Sciences Limited trades at a P/E of 43.37× and P/B of 8.25×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
RPG Life Sciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for RPG Life Sciences Limited — derived from the live tape, not yesterday's close.
RPG Life Sciences Limited last traded at ₹3,009.9 with an intraday range of ₹2,918.5–₹3,080 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹3009.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3410.10 | +400.20 | +13.30% |
| R3 | 3248.60 | +238.70 | +7.93% |
| R2 | 3164.30 | +154.40 | +5.13% |
| R1 | 3087.10 | +77.20 | +2.56% |
| PIVOT | 3002.80 | -7.10 | -0.24% |
| CURRENT | 3009.90 | — | — |
| S1 | 2925.60 | -84.30 | -2.80% |
| S2 | 2841.30 | -168.60 | -5.60% |
| S3 | 2764.10 | -245.80 | -8.17% |
| S4 | 2602.60 | -407.30 | -13.53% |
RPGLIFE is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹2957.4–₹3080
Trading Inside opening range
RPG Life Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for RPG Life Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
RPG Life Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,978.16 Cr. and reported EPS of ₹69.65.
| Metric | — | Mar 2026 |
|---|---|---|
| Revenue from Operations | — | 708 |
| Other Income | — | 26 |
| Total Income | — | 733 |
| — | 252 | |
| Gross ProfitDerived | — | 455 |
| Gross Margin %Derived | — | 64.37% |
| — | 308 | |
| EBITDA (Operating Profit)Derived | — | 147 |
| OPM %Derived | — | 20.79% |
| — | 26 | |
| Profit Before Tax (PBT) | — | 154 |
| — | 39 | |
| Effective Tax %Derived | — | 25.31% |
| Total Profit for Period | — | 115 |
| Net Profit (Owner's PAT)Derived | — | 115 |
| Net Profit Margin %Derived | — | 16.28% |
| Earnings Per Share (EPS ₹) | — | 69.64 |
| Diluted Shares Outstanding (Cr) | — | 2 |
| Other Comprehensive Income (Net of Tax) | — | -1 |
| Total Expenses (incl. D&A & Interest) | — | 579 |
| Material Cost % of RevenueDerived | — | 19.22% |
| Employee Cost % of RevenueDerived | — | 20.00% |
| Other Cost % of RevenueDerived | — | 23.58% |
| Interest Coverage (x)Derived | — | 141.13x |
| Period | Mar 2026 | Trend |
|---|---|---|
| Revenue from Operations | 708 | |
| Other Income | 26 | |
| Total Income | 733 | |
252 | ||
| Gross ProfitDerived | 455 | |
| Gross Margin %Derived | 64.37% | |
308 | ||
| EBITDA (Operating Profit)Derived | 147 | |
| OPM %Derived | 20.79% | |
26 | ||
| Profit Before Tax (PBT) | 154 | |
39 | ||
| Effective Tax %Derived | 25.31% | |
| Total Profit for Period | 115 | |
| Net Profit (Owner's PAT)Derived | 115 | |
| Net Profit Margin %Derived | 16.28% | |
| Earnings Per Share (EPS ₹) | 69.64 | |
| Diluted Shares Outstanding (Cr) | 2 | |
| Other Comprehensive Income (Net of Tax) | -1 | |
| Total Expenses (incl. D&A & Interest) | 579 | |
| Material Cost % of RevenueDerived | 19.22% | |
| Employee Cost % of RevenueDerived | 20.00% | |
| Other Cost % of RevenueDerived | 23.58% | |
| Interest Coverage (x)Derived | 141.13x |
RPG Life Sciences segment analysis : revenue and profit mix.
Disclosed business segments at RPG Life Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
RPG Life Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for RPG Life Sciences Limited.
Our AI distills the core fundamental drivers supporting RPG Life Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
RPG Life Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-free balance sheet with D/E 0.0003x provides exceptional financial flexibility and strategic optionality.
ROE 19.30% and ROCE 25.70% substantially exceed pharmaceutical sector benchmarks and peer medians.
Net profit margin 29.25% TTM far surpasses peer median ~14%, demonstrating superior pricing power.
Operating margin 20.90% quarterly reflects robust cost control and operational efficiency versus sector norms.
Promoter holding 72.95% ensures strong alignment with long-term shareholder value creation objectives.
Key Risks.
Latest quarterly EPS declined 74.5% YoY, indicating significant earnings volatility and execution risk.
Quarterly profit variance 33.70% reflects inconsistent bottom-line performance despite revenue growth.
Forward P/E 81.69x signals elevated valuation risk for new market entrants at current price levels.
Working capital swings ₹629.5 Cr negative in H1 FY26, operational strain evident in cash conversion.
Operating cash flow ₹56.50 Cr FY26 below net profit ₹115.17 Cr signals earnings quality concerns.
Flip Conditions.
Valuation risk. a P/E above 56 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 14% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.38%.
RPG Life Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — RPG Life Sciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
RPG Life Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for RPG Life Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
RPG Life Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for RPG Life Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in RPG Life Sciences Limited stood at 42.6% of traded volume, against a 20-day average of 43.8%.
RPG Life Sciences announcements: results, concalls, ratings, M&A.
Filings RPG Life Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
RPG Life Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 119 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Copy of Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the copy of Notice of…
General Updates
Pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has sent a letter to those…
Shareholders meeting
Notice of 19th Annual General Meeting of the Company
Investor decks & rating reports.
RPG Life Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue RPG Life Sciences has declared, sequenced by announce and record date.
RPG Life Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
RPG Life Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in RPG Life Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
RPG Life Sciences insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Nucleus Life Trust | Insider | 24 Dec 2024 | buy | +1.8 K | ₹39.37 L | ₹2,187.36 |
| Nucleus Life Trust | Insider | 23 Dec 2024 | buy | +10 | ₹21,700 | ₹2,170.00 |
| Nucleus Life Trust | Insider | 23 Dec 2024 | buy | +874 | ₹19 L | ₹2,174.22 |
| Nucleus Life Trust | Insider | 20 Dec 2024 | buy | +2.0 K | ₹44.17 L | ₹2,195.38 |
| Nucleus Life Trust | Insider | 20 Dec 2024 | buy | +10 | ₹21,960 | ₹2,196.00 |
| Nucleus Life Trust | Insider | 19 Dec 2024 | buy | +249 | ₹5.47 L | ₹2,197.21 |
| Nucleus Life Trust | Insider | 18 Dec 2024 | buy | +500 | ₹11.17 L | ₹2,233.00 |
| Nucleus Life Trust | Insider | 17 Dec 2024 | buy | +330 | ₹7.44 L | ₹2,254.05 |
| Nucleus Life Trust | Insider | 16 Dec 2024 | buy | +200 | ₹4.54 L | ₹2,270.05 |
About RPG Life Sciences Limited: business, sector, key facts.
What RPG Life Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
RPG Life Sciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: RPGLIFE, BSE: 532983.
RPG Life Sciences Limited is an integrated pharmaceutical company with a global reach, primarily operating in India. Their business model encompasses the entire pharmaceutical value chain, from the development and manufacture of active pharmaceutical ingredients (APIs) to the marketing and distribution of finished dosage formulations (FDFs). This vertical integration provides them with significant control over their supply chain and product quality.
A core component of their business is the production of synthetic APIs across a wide range of therapeutic areas. These include immunosuppressants, anti-psychotics, anti-anginals, anthelmintics, anti-convulsants, and anti-spasmodics, among others. This focus on API manufacturing provides a foundation for their broader pharmaceutical operations and allows them to supply both their own finished formulations and external customers.
Beyond APIs, RPG Life Sciences also manufactures and markets a vast portfolio of generic and branded finished dosage formulations (FDFs). Their product range covers an extensive spectrum of therapeutic areas, including nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional supplements, diabetology, respiratory medications, neuropsychiatry, urology, vitamins and minerals, gastrointestinal treatments, pain management, anti-diabetic medications, gynecological products, cardiovascular drugs, pediatric medications, neurological treatments, anti-dengue medications, and dermatological products. This broad portfolio caters to a diverse range of patient needs and market segments.
The company’s history dates back to 1968, showcasing a long-standing presence in the pharmaceutical industry. Currently headquartered in Mumbai, India, RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust. The company's name changed from RPG Pharmaceuticals Limited to its current name in February 2008, reflecting its broader scope of operations beyond just pharmaceuticals.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about RPG Life Sciences Limited (RPGLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of RPG Life Sciences Limited (RPGLIFE)?
The current share price of RPG Life Sciences Limited (RPGLIFE) is ₹3,009.9. Today, the stock has gained by ₹12.00 (0.40%), trading in a range of ₹2,918.5 to ₹3,080. The stock opened at ₹3,003 with a trading volume of 13,293 shares.
02Is RPG Life Sciences Limited stock a good investment for long-term?
RPG Life Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,978.16 crores, P/E ratio of 43.37, ROE of 19.30%, and ROCE of 25.70%. The dividend yield stands at 0.75%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of RPG Life Sciences Limited stock?
The 52-week high price of RPG Life Sciences Limited (RPGLIFE) is ₹3,082, while the 52-week low is ₹1,733. Currently trading at ₹3,009.9, the stock is 94.7% away from its 52-week low and 2.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy RPG Life Sciences Limited stock at the current price?
Whether to buy RPG Life Sciences Limited stock at ₹3,009.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.37 and P/B ratio of 8.25. Today's performance shows a gain of 0.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of RPG Life Sciences Limited and when is the next dividend?
RPG Life Sciences Limited offers a dividend yield of 0.75%, which means for every ₹100 invested at the current price of ₹3,009.9, you can expect to receive approximately ₹0.75 annually as dividends. The face value of the stock is ₹8.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of RPG Life Sciences Limited?
RPG Life Sciences Limited's key financial metrics include: P/E Ratio: 43.37, P/B Ratio: 8.25, ROE: 19.30%, ROCE: 25.70%, Dividend Yield: 0.75%, EPS: ₹69.65, Book Value: ₹366.04, and Debt-to-Equity: 0.03. The company's market cap stands at ₹4,978.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is RPG Life Sciences Limited stock performing today in the market?
RPG Life Sciences Limited stock opened at ₹3,003 and is currently trading at ₹3,009.9, showing a gain of ₹12.00 (0.40%). The intraday high is ₹3,080 and low is ₹2,918.5. The trading volume stands at 13,293 shares, indicating moderate market participation today.
08What is the P/E ratio of RPG Life Sciences Limited and what does it indicate?
RPG Life Sciences Limited has a Price-to-Earnings (P/E) ratio of 43.37, which means investors are willing to pay ₹43.37 for every ₹1 of earnings. With an EPS of ₹69.65, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about RPG Life Sciences Limited (RPGLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.